# Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity

> **NCT04099667** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Supernus Pharmaceuticals, Inc.** · enrollment: 272 (estimated)

## Conditions studied

- Spasticity

## Interventions

- **DRUG:** Phase 2; Low Dose MYOBLOC
- **DRUG:** Phase 2; High Dose MYOBLOC
- **DRUG:** Phase 2; Placebo
- **DRUG:** Phase 3; MYOBLOC
- **DRUG:** Phase 3; Placebo

## Key facts

- **NCT ID:** NCT04099667
- **Lead sponsor:** Supernus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-17
- **Primary completion:** 2023-04
- **Final completion:** 2024-07
- **Target enrollment:** 272 (ESTIMATED)
- **Last updated:** 2023-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04099667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04099667, "Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04099667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*